Stopping liver failure from painkiller overdose
University of Adelaide researchers have identified a key step for the future prevention of liver failure resulting from taking too much of the everyday painkiller paracetamol (also known as acetaminophen).
Published in the Proceedings of the National Academy of Sciences (PNAS), the study pinpoints a target for new treatments to prevent the potentially lethal consequences of paracetamol overdose.
"Paracetamol is the most frequently used over-the-counter pain medication," says Dr Grigori Rychkov, Senior Research Fellow in the University's School of Medical Sciences.
"Overdose of paracetamol is the most common cause of acute liver failure and the leading cause of liver damage requiring transplantation in developed countries. The precise mechanisms of liver toxicity due to paracetamol overdose, however, have remained unclear."
It has been known for a long time that paracetamol overdose is associated with toxic levels of calcium in liver cells but nobody has known how the calcium gets into the cells.
The University of Adelaide researchers have identified a channel transporting calcium across the cell membrane that is triggered by paracetamol overdose, known as Transient Receptor Potential Melanostatine2 (TRPM2). Once the channel is activated, the cells become overloaded with calcium, leading to cell death. If this continues and enough cells die, it can lead to liver failure.
The research, conducted by PhD student Ehsan Kheradpezhouh, showed in laboratory studies that when the TRPM2 channel was missing or blocked, liver cells were protected from paracetamol damage.
"We now have a potential drug target for treating paracetamol overdose and possibly some other liver-damaging poisonings," says Dr Rychkov.
Currently paracetamol overdose can be effectively treated – but only if caught within 18 hours.
"If we can block the TRPM2 channel we might be able to prevent the toxicity or extend this timeframe. If we can stop the calcium uptake and cell death, we'll be giving the liver a better chance for recovery and, hopefully, preventing complete liver failure," says Dr Rychkov.
Most read news
Organizations
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.